Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from Zidovudine- containing backbone to Truvada in HIV-1-infected patients on highly active antiretroviral therapy.

Trial Profile

Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from Zidovudine- containing backbone to Truvada in HIV-1-infected patients on highly active antiretroviral therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2015

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine; Zidovudine
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms RECOMB
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 08 Mar 2012 Results assessing the effects of treatment on the fat mass ratio presented at the 19th Conference on Retroviruses and Opportunistic Infections.
    • 22 Jul 2009 Long-term, 72-week results have been presented at IAS 2009.
    • 10 Feb 2009 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top